BioCentury
ARTICLE | Financial News

Avax raises $25.1 million

March 13, 2000 8:00 AM UTC

AVXT sold 2.26 million shares at $11.125 per share, a portion of which will be used to fund development of its M-Vax and O-Vax autologous haptenized tumor cell vaccines. M-Vax is in Phase III testing ...